A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas

Karen L. Tedesco, Jordan Berlin, Mace Rothenberg, Hak Choy, Ken Wyman, Adrian Scott Pearson, Robert Daniel Beauchamp, Nipun Merchant, A. Craig Lockhart, Yu Shyr, Carol Caillouette, Bapsi Chakravarthy

研究成果: Article同行評審

8 引文 斯高帕斯(Scopus)

摘要

Background and purpose: In vitro studies have suggested that 9-nitro-20(s)-Camptothecin (9NC/Orathecin/Rubitecan) can enhance the effects of radiation. We conducted a phase I study to assess the toxicity and determine the maximum tolerated dose of 9NC when combined with radiation in patients with locally advanced adenocarcinoma of the pancreas. Patients and methods: Eleven patients with locally advanced adenocarcinoma of the pancreas received 9NC, orally during radiation. Radiation therapy consisted of 45 Gy in 25 fractions given over 5 weeks. The starting dose of 9NC was 1 mg/m2/day. Results: Eight patients received 9NC at a dose of 1 mg/m2/day and three patients received a dose of 1.25 mg/m2/day. Dose-limiting toxicity (DLT) was defined as ≥grade 3 non-hematologic toxicity and ≥grade 4 hematologic toxicity. Dose-limiting toxicity of grade 3 nausea/vomiting developed in one patient at the first dose level. At dose level 2, two of three patients developed DLT. Both developed grade 3 nausea, fatigue, and anorexia. Additionally, one of these patients had grade 3 dehydration and the other had grade 4 leukopenia, grade 3 vomiting, and grade 3 weakness. Conclusions: 9NC, 1 mg/m2/day, can be given concurrently with radiation with acceptable toxicity.

原文English
頁(從 - 到)54-58
頁數5
期刊Radiotherapy and Oncology
76
發行號1
DOIs
出版狀態Published - 2005 七月

All Science Journal Classification (ASJC) codes

  • 血液學
  • 腫瘤科
  • 放射學、核子醫學和影像學

指紋

深入研究「A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas」主題。共同形成了獨特的指紋。

引用此